AR095538A1 - Composiciones farmacéuticas de ésteres de testosterona de cadena larga lipoequilibrados para la administración oral - Google Patents
Composiciones farmacéuticas de ésteres de testosterona de cadena larga lipoequilibrados para la administración oralInfo
- Publication number
- AR095538A1 AR095538A1 ARP140101150A ARP140101150A AR095538A1 AR 095538 A1 AR095538 A1 AR 095538A1 AR P140101150 A ARP140101150 A AR P140101150A AR P140101150 A ARP140101150 A AR P140101150A AR 095538 A1 AR095538 A1 AR 095538A1
- Authority
- AR
- Argentina
- Prior art keywords
- testosterone
- pharmaceutical compositions
- lipoequilibrated
- oral administration
- long chain
- Prior art date
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical class O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title abstract 10
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229960003604 testosterone Drugs 0.000 abstract 5
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 3
- 210000002966 serum Anatomy 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- -1 testosterone ester Chemical class 0.000 abstract 1
- 150000003515 testosterones Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/843,403 US20130225544A1 (en) | 2009-01-08 | 2013-03-15 | Lipobalanced long chain testosterone esters for oral delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095538A1 true AR095538A1 (es) | 2015-10-21 |
Family
ID=51538095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101150A AR095538A1 (es) | 2013-03-15 | 2014-03-14 | Composiciones farmacéuticas de ésteres de testosterona de cadena larga lipoequilibrados para la administración oral |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20160193227A1 (enExample) |
| EP (2) | EP2968363B1 (enExample) |
| JP (1) | JP6307711B2 (enExample) |
| KR (1) | KR102238478B1 (enExample) |
| CN (1) | CN105073118A (enExample) |
| AR (1) | AR095538A1 (enExample) |
| AU (2) | AU2014232475A1 (enExample) |
| BR (1) | BR112015020849A2 (enExample) |
| CA (1) | CA2942005C (enExample) |
| IL (1) | IL240958B (enExample) |
| MX (1) | MX2015010594A (enExample) |
| RU (1) | RU2722592C2 (enExample) |
| TW (1) | TW201521731A (enExample) |
| UY (1) | UY35445A (enExample) |
| WO (1) | WO2014145781A1 (enExample) |
| ZA (1) | ZA201507700B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180153905A1 (en) * | 2016-11-30 | 2018-06-07 | Lipocine Inc. | Oral testosterone tridecanoate therapy |
| CA3107214A1 (en) * | 2018-07-20 | 2020-01-23 | Lipocine Inc. | Liver disease |
| JP6945874B2 (ja) * | 2019-12-24 | 2021-10-06 | 一般財団法人バイオダイナミックス研究所 | 経口投与用医薬組成物 |
| CN119744172A (zh) * | 2022-06-22 | 2025-04-01 | 来普卡公司 | 十二烷酸(17-β)-3-氧代雄甾-4-烯-17-酯组合物及制备和使用方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4147783A (en) * | 1974-02-28 | 1979-04-03 | Akzona Incorporated | Oral pharmaceutical preparation |
| NL189235C (nl) * | 1974-02-28 | 1993-02-16 | Akzo Nv | Werkwijze voor de bereiding van een oraal toe te dienen farmaceutisch preparaat met androgene werking. |
| GB1567515A (en) * | 1976-05-28 | 1980-05-14 | Akzo Nv | Esters of testo-sterone and 5 -dihydro-testosterone |
| EP1313511B1 (en) * | 2000-08-23 | 2005-11-30 | Akzo Nobel N.V. | Testosterone ester formulation for human use |
| US20030022875A1 (en) * | 2001-07-27 | 2003-01-30 | Wilson Leland F. | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| JO2505B1 (en) * | 2003-03-14 | 2009-10-05 | باير شيرنغ فارما اكتنجيسيلشافت | Pharmacy methods and formulations for obtaining acceptable serum testosterone levels |
| US7138389B2 (en) * | 2004-02-09 | 2006-11-21 | University Of Washington | Oral androgen therapy using modulators of testosterone bioavailability |
| ES2930658T3 (es) * | 2005-04-15 | 2022-12-20 | Tolmar Inc | Sistemas de administración farmacéutica para medicamentos hidrofóbicos y composiciones que comprenden los mismos |
| CN101217963A (zh) * | 2005-04-15 | 2008-07-09 | 克劳拉斯医疗有限公司 | 疏水性药物给药系统及含有疏水性药物的组合物 |
| US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| US9034858B2 (en) * | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
-
2014
- 2014-03-12 TW TW103108750A patent/TW201521731A/zh unknown
- 2014-03-14 UY UY35445A patent/UY35445A/es not_active Application Discontinuation
- 2014-03-14 AR ARP140101150A patent/AR095538A1/es not_active Application Discontinuation
- 2014-03-17 KR KR1020157021653A patent/KR102238478B1/ko active Active
- 2014-03-17 EP EP14764607.9A patent/EP2968363B1/en active Active
- 2014-03-17 JP JP2016503427A patent/JP6307711B2/ja active Active
- 2014-03-17 CN CN201480010890.2A patent/CN105073118A/zh active Pending
- 2014-03-17 BR BR112015020849A patent/BR112015020849A2/pt not_active Application Discontinuation
- 2014-03-17 MX MX2015010594A patent/MX2015010594A/es active IP Right Grant
- 2014-03-17 WO PCT/US2014/030604 patent/WO2014145781A1/en not_active Ceased
- 2014-03-17 CA CA2942005A patent/CA2942005C/en active Active
- 2014-03-17 AU AU2014232475A patent/AU2014232475A1/en not_active Abandoned
- 2014-03-17 EP EP20191415.7A patent/EP3797762A1/en not_active Withdrawn
- 2014-03-17 RU RU2015128028A patent/RU2722592C2/ru active
-
2015
- 2015-08-31 IL IL240958A patent/IL240958B/en active IP Right Grant
- 2015-10-14 ZA ZA2015/07700A patent/ZA201507700B/en unknown
-
2016
- 2016-02-04 US US15/016,164 patent/US20160193227A1/en not_active Abandoned
- 2016-02-04 US US15/016,168 patent/US20160193228A1/en not_active Abandoned
-
2019
- 2019-01-08 AU AU2019200097A patent/AU2019200097B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201521731A (zh) | 2015-06-16 |
| ZA201507700B (en) | 2017-02-22 |
| KR20150129671A (ko) | 2015-11-20 |
| RU2015128028A (ru) | 2017-04-21 |
| KR102238478B1 (ko) | 2021-04-09 |
| EP2968363A1 (en) | 2016-01-20 |
| RU2722592C2 (ru) | 2020-06-02 |
| US20160193228A1 (en) | 2016-07-07 |
| US20160193227A1 (en) | 2016-07-07 |
| CN105073118A (zh) | 2015-11-18 |
| WO2014145781A1 (en) | 2014-09-18 |
| AU2019200097B2 (en) | 2021-02-04 |
| JP6307711B2 (ja) | 2018-04-11 |
| AU2019200097A1 (en) | 2019-01-31 |
| EP2968363A4 (en) | 2016-08-17 |
| BR112015020849A2 (pt) | 2017-07-18 |
| AU2014232475A1 (en) | 2015-08-06 |
| CA2942005A1 (en) | 2014-09-18 |
| EP3797762A1 (en) | 2021-03-31 |
| UY35445A (es) | 2014-10-31 |
| EP2968363B1 (en) | 2020-08-19 |
| MX2015010594A (es) | 2015-12-16 |
| IL240958B (en) | 2019-07-31 |
| JP2016514706A (ja) | 2016-05-23 |
| IL240958A0 (en) | 2015-11-30 |
| CA2942005C (en) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015000138A (es) | Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina. | |
| CO6341565A2 (es) | Inhibidores macrociclicos de serina proteasas de hepatitis c | |
| CL2012002424A1 (es) | Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende. | |
| BR112015022047A8 (pt) | uso de uma composição compreendendo nanopartículas contendo um fármaco da família limo e uma albumina | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
| AR084433A1 (es) | Inhibidores de la faah y composiciones farmaceuticas que los contienen | |
| UY32455A (es) | Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia | |
| EA201200096A1 (ru) | Фармацевтическая композиция ингибитора протеазы вируса гепатита c | |
| CO6410279A2 (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
| AR080491A1 (es) | Formulaciones orales y sales lipofilicas de metilnaltrexona | |
| CL2011000589A1 (es) | Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
| EA201391285A1 (ru) | Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена | |
| MX370795B (es) | Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida y/o triptófano para influir positivamente en la microbiota intenstinal. | |
| BR112014014795A2 (pt) | sistema de pélete de multiunidade de liberação imediata | |
| UA110979C2 (uk) | Рідка фармацевтична композиція, яка включає нітизинон | |
| CL2015003468A1 (es) | Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d. | |
| BR112014008400A2 (pt) | derivados de 2-carboxamida cicloamino ureia em combinação com os inibidores de hsp90 para o tratamento de doenças proliferativas | |
| MX2016005437A (es) | Derivados de n-(1-hidroxi-3-(pirrolidinil)propan-2-il)pirrolidin-3 -carboxamida como inhibidores de glucosilceramida sintasa. | |
| MX2022001796A (es) | Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. | |
| AR095538A1 (es) | Composiciones farmacéuticas de ésteres de testosterona de cadena larga lipoequilibrados para la administración oral | |
| AR090975A1 (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida | |
| AR090073A1 (es) | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos | |
| BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
| CO7170181A2 (es) | Nueva composición de alfentanilo para el tratamiento del dolor agudo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |